6/29/2011 8:50:51 AM
MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced that the company has entered into an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to the company’s molecular testing platform. This platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Financial terms of the agreement are undisclosed.
comments powered by